{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:37:42Z","timestamp":1773272262438,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/bf03401336","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T05:30:48Z","timestamp":1533706248000},"page":"222-228","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of combined parenteral and oral steroid therapy in Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"13","author":[{"given":"Biljana Nedeljkovic","family":"Beleslin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Ciric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Zarkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavica","family":"Savic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozo","family":"Trbojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"BF03401336_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS, 2010 Graves ophthalmopathy. N Engl J Med 362: 726\u2013738.","journal-title":"N Engl J Med"},{"key":"BF03401336_CR2","first-page":"747","volume":"14","author":"HB Burch","year":"1993","unstructured":"Burch HB, Wartofsky L, 1993 Graves ophthalmopathy: current concepts regarding pathogenesis and treatment. Endocr Rev 14: 747\u2013793.","journal-title":"Endocr Rev"},{"key":"BF03401336_CR3","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C, 2000 Management of Graves ophthalmopathy: reality and perspectives. Endocr Rev 21: 168\u2013199.","journal-title":"Endocr Rev"},{"key":"BF03401336_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, et al, 2008 Consensus statement of the European group on Graves orbitopathy (EUGOGO) on management of Graves orbitopathy. Thyroid 18: 336\u2013346.","journal-title":"Thyroid"},{"key":"BF03401336_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ, 2011 Intravenous glucocorticoids for Graves orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab 96: 320\u2013332.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03401336_CR6","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, 2012 Efficiacy of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97: 4454\u20134463.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03401336_CR7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1136\/bmj.297.6663.1574","volume":"297","author":"P Kendall-Taylor","year":"1988","unstructured":"Kendall-Taylor P, Crombie AL, Stephenson AM, et al, 1988 Intravenous methylprednisolone in the treatment of Graves ophthalmopathy. Br Med J 297: 1574\u20131578.","journal-title":"Br Med J"},{"key":"BF03401336_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","volume":"55","author":"AJ Dickinson","year":"2001","unstructured":"Dickinson AJ, Perros P, 2001 Controversies in the clinical evaluation of active thyroid associated orbitopathy: use of a detailed protocol with compartice photographs for objective assessment. Clin Endocrinol (Oxf) 55: 283\u2013303.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03401336_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman C, 1987 Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin N Am 16: 391\u2013407.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"BF03401336_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L, 1997 Clinical activity score as a guide in the management of patients with Graves ophthalmopathy. Clin Endocrinol (Oxf) 47: 9\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03401336_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al, 1998 Relation between therapy for hyperhyroidism and the course of Graves ophthalmopathy. N Engl J Med 338: 73\u201378.","journal-title":"N Engl J Med"},{"key":"BF03401336_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee CB, Dekker FW, Mourits MP, et al, 2001 Interpretation and validity of changes in scores on the Graves\u2019 ophalmopathy quality of life questionnaire (GO-QoL) after different treatment. Clin Endocrinol (Oxf) 54: 391\u2013398.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03401336_CR13","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1136\/bmj.297.6663.1574","volume":"297","author":"P Kendall-Taylor","year":"1998","unstructured":"Kendall-Taylor P, Crombie AL, Stephenson AM, et al, 1998 Intravenous methylprednisolone in the tretment of Graves\u2019 ophthalmopathy. Br Med J 297: 1574\u20131578.","journal-title":"Br Med J"},{"key":"BF03401336_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","volume":"80","author":"R Kaupinen-Makelin","year":"2002","unstructured":"Kaupinen-Makelin R, Karma A, Leinomen E, et al, 2002 High dose intravenous methylprednisolone puis therapy versus oral prednisone for thyroid associated ophthalmopathy. Ophthalmol Scand 80: 316\u2013321.","journal-title":"Ophthalmol Scand"},{"key":"BF03401336_CR15","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda LM, et al, 2001 Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562\u20133567.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03401336_CR16","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M, 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90: 5234\u20135240.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03401336_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1530\/eje.0.1380368","volume":"138","author":"RD Utiger","year":"1998","unstructured":"Utiger RD, 1998 Effects of smoking on thyroid function. Eur J Enocrinol 138: 368\u2013369.","journal-title":"Eur J Enocrinol"},{"key":"BF03401336_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF03345276","volume":"27","author":"L Hegedius","year":"2004","unstructured":"Hegedius L, Brix TH, Vestergaard P, 2004 Relationship between cigaretes smoking and Graves ophthalmopathy. J Endocrinol Invest 27: 265\u2013271.","journal-title":"J Endocrinol Invest"},{"key":"BF03401336_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/thy.2006.0267","volume":"17","author":"R Moli Le","year":"2007","unstructured":"Le Moli R, Baldeschi I, Saeed P, Regensburg N, Mourits MP, Wiersinga WM, 2007 Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves ophthalmopathy. Thyroid 17: 357\u2013362.","journal-title":"Thyroid"},{"key":"BF03401336_CR20","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/jc.2012-1275","volume":"97","author":"P Laurberg","year":"2012","unstructured":"Laurberg P, Berman DC, B\u00fclow Pedersen I, Andersen S, Carl\u00e9 A, 2012 Incidence and clinical presentation of moderete to severe Graves\u2019 Orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97: 2325\u20132332.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03401336\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03401336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03401336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T22:15:18Z","timestamp":1534371318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03401336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BF03401336"],"URL":"https:\/\/doi.org\/10.1007\/bf03401336","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}